Evidence map›Paper›PMID 30022448›Full record

ArticleMolecular and cellular biochemistry2019

Silibinin ameliorates amylin-induced pancreatic β-cell apoptosis partly via upregulation of GLP-1R/PKA pathway.

Jing Yang, Yue Sun, Fanxing Xu, Weiwei Liu, Yingsi Mai, Toshihiko Hayashi, Shunji Hattori, Yuko Ushiki-Kaku, Satoshi Onodera, Shin-Ichi Tashiro and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Jing YangWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China.
Yue SunWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China.
Fanxing XuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China.
Weiwei LiuWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China.
Yingsi MaiWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China.
Toshihiko HayashiWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China.
Shunji HattoriNippi Research Institute of Biomatrix, Toride, Ibaraki, 302-0017, Japan.
Yuko Ushiki-KakuNippi Research Institute of Biomatrix, Toride, Ibaraki, 302-0017, Japan.
Satoshi OnoderaDepartment of Clinical and Biomedical Sciences, Showa Pharmaceutical University, Tokyo, 194-8543, Japan.
Shin-Ichi TashiroDepartment of Medical Education and Primary Care, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, Japan.
Takashi IkejimaWuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, 110016, Liaoning, People's Republic of China. ikejimat@vip.sina.com.
Shenyang Pharmaceutical University · CNJapan Institute of Leather Research · JPKogakuin University · JPKyoto Prefectural University of Medicine · JPShowa Pharmaceutical University · JP

Funding

Doctoral Starting up Foundation of Liaoning Science and Technology Department 51120390Foundation of Liaoning Education Committee 51120427Innovation and Entrepreneurship Training Program of Shenyang Pharmaceutical University 201710163000006
6 · The paper itself

Abstract

The objective was to investigate the mechanism of the protective effect of silibinin on amylin/Aβ

Indexed as

Amylin Receptor AgonistsAnimalsAntineoplastic Agents, PhytogenicApoptosisCyclic AMP-Dependent Protein KinasesGlucagon-Like Peptide-1 ReceptorInsulinomaInsulin-Secreting CellsIslet Amyloid PolypeptidePancreatic NeoplasmsRatsSignal TransductionSilybinTranscriptional ActivationTumor Cells, CulturedUp-RegulationAmylin Receptor AgonistsAntineoplastic Agents, PhytogenicCyclic AMP-Dependent Protein KinasesGlucagon-Like Peptide-1 ReceptorIslet Amyloid PolypeptideSilybinApoptosisGLP-1RINS-1 cellsPKASilibinin

Identifiers

PMID30022448
OpenAlexW2884309088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.